ArticleOncotarget2021
Targeting cancer associated fibroblasts to enhance immunotherapy: emerging strategies and future perspectives.
Article in Oncotarget, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- T Cell Exhaustion and Activation Markers in Pancreatic Cancer: A Systematic Review.Journal of gastrointestinal cancer · 2024Pooled it
- TRKB-based signature identifies high-risk squamous cell carcinoma cases and TRKB blockade reprograms tumor and stromal cells toward suppressive phenotypes.Journal of biomedical science · 2026Article
- Review
- POSTN is exclusively activated in cancer-associated fibroblasts and leads to unfavorable prognosis of patients with gastric cancer.Molecular and clinical oncology · 2025Article
- Role of the tumor microenvironment in cancer therapy: unveiling new targets to overcome drug resistance.Medical oncology (Northwood, London, England) · 2025Review
- Biophysical perspectives to understanding cancer-associated fibroblasts.APL bioengineering · 2024Review
- Metabolic targeting of cancer associated fibroblasts overcomes T-cell exclusion and chemoresistance in soft-tissue sarcomas.Nature communications · 2024Article
- Heterogeneity of cancer-associated fibroblasts and tumor-promoting roles in head and neck squamous cell carcinoma.Frontiers in molecular biosciences · 2024Review
- Unravelling heterogeneous effects of cancer‑associated fibroblasts on poor prognosis markers in breast cancer EM‑G3 cell line:Oncology reports · 2024Article
- Targeting circulating tumor cells to prevent metastases.Human cell · 2024Review
- Identification of a cancer associated fibroblasts-related index to predict prognosis and immune landscape in ovarian cancer.Scientific reports · 2023Article
- Article
- Article
- Decoding the Complexity of Immune-Cancer Cell Interactions: Empowering the Future of Cancer Immunotherapy.Cancers · 2023Review
- Metastatic colorectal cancer: mechanisms and emerging therapeutics.Trends in pharmacological sciences · 2023Review
- Effect of activating cancer-associated fibroblasts biomarker TNC on immune cell infiltration and prognosis in breast cancer.Annals of medicine · 2023Article
- Implications for Immunotherapy of Breast Cancer by Understanding the Microenvironment of a Solid Tumor.Cancers · 2022Review
- Key promoters of tumor hallmarks.International journal of clinical oncology · 2022Review
- Senescence and Immunoregulation in the Tumor Microenvironment.Frontiers in cell and developmental biology · 2021Review
- The Cellular Origins of Cancer-Associated Fibroblasts and Their Opposing Contributions to Pancreatic Cancer Growth.Frontiers in cell and developmental biology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer associated fibroblasts are a prominent component of the tumour microenvironment in most solid cancers. This heterogeneous population of cells are known to play an important role in tumour progression and recent studies have demonstrated that CAFs may confer resistance to checkpoint immunotherapy, suggesting that targeting these cells could improve response rates. However, effective clinical strategies for CAF targeting have yet to be identified. In this editorial, we highlight current limitations in our understanding of CAF heterogeneity, and discuss the potential and possible approaches for CAF-directed therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.